๐๏ธ Verified NIH Record โข Updated 2026-05-04
ACP-196 (Acalabrutinib), a Novel Bruton Tyrosine Kinase (BTK) Inhibitor, for Treatment of Chronic Lymphocytic Leukemia, Richter's Syndrome or Prolymphocytic Leukemia (NCT02029443)
A Phase 1/2, Multicenter, Open-label, and Dose-escalation Study of ACP-196 in Subjects With Chronic Lymphocytic Leukemia, Richter's Syndrome or Prolymphocytic Leukemia
๐ต Active, Not Recruiting Phase1 / Phase2 ๐ Investigational Drug / Biologic Sponsor: Acerta Pharma BV
๐ฉบ Plain-English Summary (8th-Grade Level)
This study is evaluating the safety and efficacy of a new BTK inhibitor, acalabrutinib, for the treatment of chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).
Who can join: Review the eligibility criteria below.
Location: Research Site โ Boston, Massachusetts
Age range: 18 Years
๐งช Interventions in This Study
๐ "Do I Qualify?" โ 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria โ
๐ All Participating Trial Locations (12 Sites)
- Research Site โ Boston, Massachusetts
- Research Site โ New Hyde Park, New York
- Research Site โ New York, New York
- Research Site โ Columbus, Ohio
- Research Site โ Fort Worth, Texas
- Research Site โ Salt Lake City, Utah
- Research Site โ Seattle, Washington
- Research Site โ Tacoma, Washington
- Research Site โ Milan,
- Research Site โ Leeds,
- Research Site โ London,
- Research Site โ Oxford,
๐ฐ Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA ยง 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Chronic Lymphocytic Leukemia
- Acalabrutinib and Obinutuzumab for the Treatment of Chronic Lymphocytic Leukemia โ Houston, Texas
- Pirtobrutinib and Venetoclax With MRD Detection for Previously Untreated Chronic Lymphocytic Leukemia โ Rochester, Minnesota
- A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006) โ Anchorage, Alaska
- Economic Analysis of Alliance A041202 CLL Study โ Calgary, Alberta
- A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL โ Chandler, Arizona
- Study of Acalabrutinib (ACP-196) Versus Ibrutinib in Previously Treated Participants With High Risk Chronic Lymphocytic Leukemia (CLL) โ Phoenix, Arizona
Explore by condition: All Chronic Lymphocytic Leukemia clinical trials
๐ก How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.